Comparison of M-Vax Plus Low Dose Interleukin-2 Versus Placebo Vaccine Plus Low Dose Interleukin-2 in Patients With Stage IV Melanoma.
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2015
At a glance
- Drugs BCG; Cyclophosphamide; Interleukin-2; Melanoma vaccine DNP-VACC
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms MVALDI
- 02 Dec 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2021 as reported by ClinicalTrials.gov.
- 02 Dec 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2019 as reported by ClinicalTrials.gov.
- 02 Dec 2015 Status changed from active, no longer recruiting to not yet recruiting as reported by ClinicalTrials.gov.